Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in Adolescent Patients With Seasonal Allergic Rhinitis
NCT07678931Phase 3Recruiting
- Sponsor
- Chengdu Kangnuoxing Biopharma, Inc.
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Chengdu Kangnuoxing Biopharma, Inc.. Started Aug 2026; status: recruiting.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07678931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678931.